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Abstract: Aquacel Ag® (ConvaTec, Princeton, NJ, USA) is a new hydrofiber wound dressing 
consisting of soft non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. 
It is a moisture-retention dressing, which forms a gel on contact with wound fluid and has 
antimicrobial properties of ionic silver. We present a current literature review on Aquacel Ag®, 
of both in vitro and in vivo efficacy and clinical applications. In vitro and in vivo studies have 
demonstrated the wide antimicrobial properties of Aquacel Ag®, and additionally demonstrated 
the cytotoxicity of ionic silver to keratinocytes and fibroblasts that cause delay in wound 
re-epithelialization. Clinical studies confirmed that Aquacel Ag® is an effective and safe dress-
ing for a variety of wound types, both acute and chronic. Incorporation of ionic silver into the 
hydrofibers does not cause undue alteration in the performance properties of the base dressing, 
which continues to provide favorable wound moisture and exudate management. The addition 
of ionic silver reduces local pain and dressing changes, and provides significant broad-spectrum 
antimicrobial properties, with no delay in wound healing.
Keywords: Aquacel Ag®, silver, wound dressing, hydrofiber, carboxymethylcellulose
Introduction
The ideal dressing needs to ensure that the wound remains moist with exudates but 
not macerated; free of infection, excessive slough, toxic chemicals, particles, and 
fibers; at the optimum temperature and pH for healing; and undisturbed by the need 
for frequent changes.
Aquacel® Hydrofiber dressing (ConvaTec, Princeton, NJ, USA) is a moisture-
retention dressing that consists of soft non-woven sodium carboxymethylcellulose 
fibers which forms a gel on contact with wound fluid. The gel promotes a moist wound-
healing environment yet retains wound exudates by vertical absorption. Fibrin collects 
between the dressing and wound surface and acts as an adhesive, fixing the dressing in 
place and providing adherence of the dressing to the wound without ingrowth of tissue 
into the dressing. This was found to be beneficial for both caregivers and patients in 
terms of ease of application and removal, and reduction in pain at dressing change. 
Aquacel has been applied to many types of wound care with favorable results and 
cost-effectiveness.1–7
Silver has been used widely for many years in wound care to help manage local 
infection. Historically, silver has been presented as metallic (silver foil), solution 
(eg, silver nitrate), or cream (eg, silver sulfadiazine). Ionic silver (Ag+), which 
is the oxidized active state of silver, has received renewed interest and research 
for use as a prophylactic antimicrobial agent in wound dressings due to its broad Therapeutics and Clinical Risk Management 2010:6 22
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spectrum antibacterial range, including aerobic, anaerobic, 
Gram-negative and Gram-positive bacteria, as well as yeast 
and fungi. The antimicrobial effect of silver can be explained 
by various mechanisms: silver interferes with the respiratory 
chain in the cytochromes of microbacteria; additionally, 
silver ions also interfere with components of the microbial 
electron transport system, bind DNA, and inhibit DNA 
replication. Little current evidence of emerging microbial 
resistance to silver has been reported.8–12
Dressings, as opposed to cream formulations, are designed 
to have a more controlled and prolonged release of silver 
during wear-time. Aquacel Ag® dressing combines 1.2% 
silver to Aquacel Hydrofiber, which is distributed through-
out the dressing material. The concept of Aquacel Ag® is to 
retain the hydrofiber’s physical properties with the additional 
benefits of silver, which is slowly released into the wound for 
up to 2 weeks, creating a moist antimicrobial environment. 
The dressing entraps microorganisms within its fibers. Con-
trolled release of silver ions reduces the bioburden within the 
dressing, minimizing the risk of infection.
Aquacel Ag® is intended for the management of a wide 
range of acute and chronic wounds, based on the clinical 
experience with Aquacel hydrofiber dressing. Various 
silver-impregnated wound dressings are available for the 
management of critically colonized and locally infected 
wounds. These dressings differ in structure and physical 
properties, the form and amount of silver contained in the 
dressing, and the mechanism by which silver is delivered.
This article provides a review of current data regarding 
the use of Aquacel Ag® in wound care.
In vitro efficacy
The significant antimicrobial effect of silver raised con-
cerns regarding its cytotoxic effect on host cell viability and 
proliferation in wound tissue. The in vitro cytotoxic safety 
and antimicrobial efficacy of Aquacel Ag® were studied and 
compared to other commercially available silver-containing 
dressings.
Paddle-Ledinek and colleagues13 studied the effect of 
different wound dressings on cell viability and proliferation. 
Keratinocyte cultures were exposed for 40 hours to extracts 
of wound dressings. Silver-containing dressings (carboxy-
methylcellulose, nanocrystalline, polyurethane foam, and 
hydrocolloid/alginate) induced greater cytotoxicity and 
morphological disorder compared to dressings with no silver 
impregnated. Aquacel Ag® was found to contain approxi-
mately 20 µg/cm2 of silver and induced the death of almost 
all exposed keratinocytes.8,13 The authors’ recommendation 
was to use silver-based dressings with caution in situations 
where rapidly proliferating cells may be harmed, as in donor 
sites, superficial burns, and cultured cell applications.
Further evidence of the in vitro cytotoxic effect of 
Aquacel Ag® was presented by Burd and colleagues,8 who 
found Aquacel Ag® to be lethal to monolayer cultured kera-
tinocytes and fibroblasts in a comparative study of the cyto-
toxicity of silver-based dressings. Furthermore, epidermal 
reepithelialization, examined in a pig mid-dermis explant cul-
ture model, was delayed in silver-based dressings compared 
to non-silver controls. Explants treated with Aquacel Ag® 
had a significantly smaller re-epithelialization area per hair 
follicle compared to non-silver control.8
Duc and colleagues14 performed an in vitro cytotoxic 
analysis of a variety of antiseptic medications on skin sub-
stitutes and autograft. They found that Aquacel Ag® was 
not toxic to autograft or skin substitutes based on assess-
ments of graft histology and metabolism, including RNA 
staining.14 The antimicrobial spectrum of activity and efficacy 
of Aquacel Ag® was examined in vitro and compared to 
other silver-impregnated dressings in numerous studies.15–21 
Aquacel Ag® was shown to be microbicidal against a wide 
range of burn wound and chronic wound pathogens, including 
aerobic and anaerobic bacteria, antibiotic-resistant bacteria, 
yeast.15–21 Antibiotic-resistant bacteria included methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococci (VRE), Pseudomonas aeruginosa (PA), 
and Serratia marcescens (SM). The microbicidal effect was 
sustained over a period of 14 days.15
Antibacterial, physical, and chemical comparisons of the 
various silver-containing dressings demonstrated wide vari-
ance in their antipathogenic capability.16–18,20,21 Parsons and 
colleagues20 plotted silver content and silver release at 3 and 
48 hours against antibacterial activity at 7 days of culture for 
each silver-containing dressing. They found that antimicro-
bial activity is not directly correlated with increasing silver 
release. Aquacel Ag® demonstrated superior antibacterial 
activity, compared to other silver-containing dressings, par-
ticularly nanocrystalline silver-containing dressing.18,20,21 Its 
fluid handling properties, moisture retention, and conform-
ability were also superior.
Other studies showed superior antibacterial activity of 
nanocrystalline dressings compared to Aquacel Ag®,16,17 
although Castellano and colleagues16 demonstrated that both 
Aquacel Ag® and nanocrystalline dressings have inferior 
antibacterial properties compared to commonly used topical 
antimicrobial agents, including silver sulfadiazine, mafenide 
acetate, and silver calcium alginate.Therapeutics and Clinical Risk Management 2010:6 23
Hydrofiber wound dressing with silver Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Gaisford and colleagues22 reported an in vitro method for 
the quantitative determination of the antimicrobial efficacy of 
silver-containing dressings. By using isothermal calorimet-
ric measurements, the authors estimated the silver load and 
bioavailability in the wound environment. Results showed 
that not all of the silver in Aquacel Ag® was bioavailable, 
reducing the potential for silver toxicity and extending the 
bactericidal effect over time.22
Other effects of silver containing dressings on wound 
healing were studied. Aquacel Ag® and other silver-containing 
dressings were found to sequester matrix wound metallopro-
teinases in vitro.23 This finding may have a positive effect on 
wound healing in chronic recalcitrant wounds.
In vivo efficacy
Animal models have been used to study the performance 
and cytotoxicity of Aquacel Ag® and other silver-based 
dressings in vivo.8,24,25 In a partial thickness exudating 
porcine model, two common silver-containing dressings 
were tested for exudate management, wound-site adher-
ence, dressing integrity, retention of dressing debris within 
wounds, and wound tissue integrity.24 Aquacel Ag® was 
found to be less effective in exudate management com-
pared to hydrocolloid/alginate. On exposure to exudates, 
Aquacel Ag® formed a fluid gel with minimal mechanical 
integrity and low adherence to the wound bed. There was 
some level of trapped dressing debris with ensuing foreign 
body reaction.
In a full-thickness infected mouse wound model, Yates 
and colleagues showed that infected wounds treated with 
Aquacel Ag® had lower wound bacteria loads, superior wound 
tensile strength, and accelerated epithelialization compared 
to untreated infected wounds.25 Histological analysis corre-
lated with macroscopic findings, demonstrating accelerated 
proliferation, remodeling, and maturation of the wound in the 
Aquacel Ag® treated group. Aquacel Ag® showed significant 
wound bacterial reduction compared to Aquacel treated- and 
untreated wounds.25
The cytotoxic effect of Aquacel Ag® was studied on an 
excisional mouse wound model.8 Silver-based dressings 
showed delayed or inhibited wound re-epithelialization com-
pared to non-silver control dressing. The authors commented 
that previous studies demonstrating enhanced wound healing 
with silver was performed on acute incisional wounds where 
keratinocyte proliferation is not a major feature.8,26
Dressing requirements in a chronic wound healing situ-
ation are different when control of the wound bioburden is 
more important.9,10 Aquacel Ag® showed decreased inhibition 
of wound epithelialization compared to nanocrystalline and 
hydrocolloid silver-based dressings.8
Clinical applications
Multiple clinical studies have been performed to assess 
Aquacel Ag®’s effectiveness for the treatment of a variety 
of acute and chronic wounds, managed in acute and chronic 
settings, as summarized in Table 1.27–39
Aquacel Ag® has been evaluated for use in adult and 
pediatric patients with partial-thickness burns.27,28,32,33,35–37 
Caruso and colleagues performed a phase II non-
comparative trial using Aquacel Ag® in partial thickness 
burns and found a good wound re-epithelialization rate, 
with reduced wound pain, good conformability, and ease 
of use.28 Some side-effects were noted, including burn-
ing on initial application and minor difficulties with joint 
movement due to dressing hardening over the joint. All 
side-effects were classified as minor and did not cause any 
functional deficits.28 Caruso et al continued their research 
with a stratified, randomized prospective, though unblinded 
study, comparing Aquacel Ag® and silver sulfadiazine 
(SSD) in the management of partial thickness burns.27 
Aquacel Ag® was associated with significantly less pain 
and anxiety during dressing changes, significantly fewer 
procedural and opiate medications, significantly less 
burning and stinging during wear, a significantly better 
achievement of normal scar height by the end of study 
treatment, significantly fewer dressing changes, less nurs-
ing time, and greater cost-effectiveness than SSD. SSD was 
associated with significantly greater flexibility and greater 
ease of movement than the Aquacel Ag® dressing. Both 
dressings had comparable overall burn wound healing and 
incidence of adverse events, including infection rates, as 
well as total dressing cost.27
Other clinical studies on partial thickness burns treat-
ment showed good wound healing, reduced pain, fewer 
dressing changes, and better cost-effectiveness Aquacel Ag® 
compared to standard treatment.32,33,35–37 In patients with 
acute split-thickness skin graft donor sites and acute 
traumatic wounds,31,34 Aquacel Ag® showed superior 
re-epithelialization rates and ease of use, and was associ-
ated with less pain on dressing removal, in comparison with 
standard treatment.
Aquacel Ag® was also evaluated for the treatment of 
chronic wounds,29,30,38,39 which have an increased bacterial 
burden that can impair healing, albeit without all the clini-
cal signs of infection. Silver can provide a mechanism for 
controlling the wound bacterial burden. Two open-label Therapeutics and Clinical Risk Management 2010:6 24
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noncomparative case studies evaluated Aquacel Ag® in 
the management of chronic wounds of different etiologies, 
including clinically infected wounds.29,39 Most patients treated 
with Aquacel Ag® had a decrease in wound size, improved 
maceration, and decreased slough.29 There were no serious 
adverse events. One patient reported temporary burning and 
stinging on initial application, and one on malposition of the 
dressing.29,39 In an economic analysis of one month treatment 
of chronic venous leg ulcers with various silver dressings, 
Aquacel Ag® was less cost effective than silver-releasing 
foam dressings.38
Jude and colleagues30 performed a prospective random-
ized controlled study on Aquacel Ag® versus calcium 
alginate dressings in managing nonischemic foot ulcers 
in patients with diabetes. Aquacel Ag® was found to 
be safe, with minor dressing-related adverse effects 
encountered in the study. Both dressings showed similar 
wound-healing capabilities, but the group treated with 
Aquacel Ag® had significantly greater depth reduction 
and overall wound bed improvement. This was emphasized 
in a subset of patients that were treated with systemic 
antibiotics during the study period, suggesting a potential 
synergy between topical silver dressings and systemic 
antibiotics.30
Discussion
The search for the ideal dressing is ongoing, with many new 
advanced dressings on the market aspiring to achieve this 
status. No currently available dressing suits all patients or 
all wounds, at all stages of the healing process. The aim of 
new dressings is to improve the quality of care and clinical 
outcomes coupled with a significant reduction in the cost of 
providing such care.
The development of wound infection is an ongoing 
problem for many patients. It is well documented that if a 
wound becomes infected, normal healing is disrupted as the 
inflammatory phase becomes chronic, suppressing the regen-
erative phase.9–12 Infected wounds may cause great distress 
in terms of associated morbidity and mortality, increased 
length of hospital admission, delayed wound healing, and 
increased discomfort; they also increase health care costs 
significantly.9–12
Table 1 Comparison between clinical studies done on Aquacel Ag®
Authors  
and references




Aquacel Ag®  
versus
Endpoint/outcome Results
Caruso28 Prospective Phase ii 22 Partial thickness 
burns
Non-comparative Clinical performance Positive re-epithelialization  
rate, ease of use, comfort,  
flexibility, conformability
Lohana33 Prospective Phase ii 22 Pediatric partial  
thickness burns
Non-comparative Clinical performance Good wound healing, reduced 
pain, ease of use, comfortable
Coutts29 Case series 30 Chronic wounds Non-comparative wound healing Decreased size, exudate, and 
maceration, increased  
granulation tissue
vanscheidt39 Prospective 15 Chronic leg ulcer Non-comparative Clinical performance Reduction in pain, wound 
slough, and size, improved 
wound healing
Paddock36 Retrospective 38 Pediatric partial  
thickness burns
Silver sulfadiazine  Cost-effectiveness Reduced hospital costs,  
greater cost-effectiveness
Saba37 Retrospective 10 Pediatric partial  
thickness burns
Xeroform gauze  
with bacitracin zinc
Clinical performance Reduced in-hospital stay  
and pain, shorter  
re-epithelialization
Caruso27 Prospective,  
Randomized
42 Partial thickness 
burns
Silver sulfadiazine  Cost-effectiveness Less pain and burning, fewer  
dressing changes, greater  
cost-effectiveness
Lohsiriwat34 Prospective,  
Randomized
11 Split-thickness skin 
graft donor sites
Paraffin gauze Clinical performance Reduced pain and faster  
re-epithelialization
Jurczak31 Prospective,  
Randomized




Clinical performance Better pain management,  
comfort, exudate handling,  
and ease of use
Jude30 Prospective,  
Randomized
67 Diabetic foot  
ulcers
Calcium alginate wound healing More reduction in ulcer  
depth and better  
infection controlTherapeutics and Clinical Risk Management 2010:6 25
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Aquacel Ag® was developed with the goal of combining 
the benefits of Aquacel carboxymethylcellulose hydrofiber 
in wound healing, with the addition of silver as a proven 
antimicrobial.25 Resurgence in the use of silver-based 
antiseptics may be linked to their broad-spectrum activ-
ity and far lower propensity to induce bacterial resistance 
than antibiotics, in parallel with recent availability of 
new, advanced dressings impregnated with this antiseptic 
agent.9–12 The addition of silver to advanced dressings with 
proven healing benefits has advantages in both acute and 
chronic wounds. In acute wounds, especially partial thick-
ness burn wounds, the antibacterial substance is intended 
to prevent infection, while in chronic wounds the goal is 
to reduce bacterial load.
The integration of silver into these dressings has been 
shown to provide a wide range of antibacterial activity in 
vitro, including demonstrated toxicity against highly resistant 
bacteria.15,17–21 The antimicrobial efficacy of silver-containing 
dressings may vary, depending on the mechanism of silver’s 
bioavailability. In Aquacel Ag®, silver is displaced from the 
carboxymethylcellulose carrier as it is hydrated; thereby 
achieving a gradual, sustained release, and thus sustained 
antimicrobial capability.15,17–21 Perhaps bacteria are also 
sequestered by the carboxymethylcellulose.
In addition to its wide range of antimicrobial activity, 
silver may have other beneficial effects on the wound bed. 
Reduction of matrix metalloproteinases, inhibition of proin-
flammatory cytokines, and a higher frequency of apoptosis 
alter inflammatory processes in the wound.23
The use of silver raised concerns regarding wound 
cytotoxicity. Indeed, the cytotoxicity of Aquacel Ag® was 
found to be multifactorial, relating to silver content and 
affinity for moisture, as well as silver composition – the 
chemical and physical form of the silver.8 In vitro and 
in vivo studies have shown that silver has a cytotoxic 
effect against rapidly proliferating cells, including kera-
tinocytes and fibroblasts, and thus may delay wound 
epithelialization.8,13 However, clinical studies in patients 
with partial-thickness wounds (partial-thickness burns 
and skin graft donor-sites) demonstrated good wound re-
epithelialization, with no delay in wound healing.27,28,32–37 
Moreover, an in-vivo infected wound model demonstrated 
similar wound healing properties between Aquacel and 
Aquacel Ag®, with significant lower bacterial loads in 
the Aquacel Ag® treated group.25 This can be explained by 
the fact that the wound healing process has many phases 
and levels, and only clinical trials, as opposed to in vitro 
studies, can effectively assess the net effect of a dressing on 
the wound healing process. The presence of serum plasma 
alters the silver dissociation in interactions between wound 
tissue and silver.
In addition, there is a concern that pathogens may develop 
resistance to silver if it is widely used in medical devices. 
Resistance is thought to develop when bacteria are exposed 
to low levels of silver for extended periods of time. To date, 
no clinical study has reported bacterial resistance to silver 
during treatment with Aquacel Ag®.27–39
Another concern relating to the use of advanced 
silver-impregnated dressings is the cost of care. Silver-
containing dressings are relatively expensive, although the 
higher cost is partially offset by; reduced use of secondary 
gauze, retention dressings, and improved wound heal-
ing together with the reduced costs of other care. Cost-
effectiveness calculations comparing Aquacel Ag® to standard 
of care in patients with acute and chronic wounds showed 
favorable results using Aquacel Ag®.27,32,33,36–38
Aquacel Ag® was found to be a safe dressing, with 
only minor adverse effects reported in clinical trials.27–39 
Adverse effects included local burning and stinging on 
initial application, dressing hardening over joints, dressing 
slippage, and isolated cases of deep infection in initially 
infected wounds. Patients treated with Aquacel Ag® reported 
favorable outcome regarding ease of use, conformability, 
limited dressing changes, and reduced pain from dressing 
changes.27–39
The majority of clinical studies with Aquacel Ag® 
and other advanced silver-containing dressings have 
limitations, namely lack of treatment blinding, lack of 
stratification and randomization, lack of objective wound 
pain assessment, heterogeneous study populations, and the 
lack of objective wound healing assessment. Most studies 
provided low levels of evidence on clinical efficacy; there 
have been only a few prospective randomized controlled 
studies.30,31,34 Furthermore, many studies on the efficacy 
of new silver products are sponsored by the manufactur-
ers, who tend to promote the benefits of the product under 
investigation.
Conclusions
Aquacel Ag® was shown to be an effective and safe 
dressing for a variety of wound types, both acute and 
chronic. Incorporation of ionic silver into the hydrofi-
bers did not cause undue alteration in the performance 
properties of the base dressing, which continues to provide 
favorable wound moisture and exudate management. The 
addition of ionic silver reduces local pain and dressing Therapeutics and Clinical Risk Management 2010:6 26
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changes, and provides significant broad-spectrum 
antimicrobial properties. Further prospective randomized 
controlled studies are needed to assess the appropriate 
indications for the use of Aquacel Ag®, and compare its 
performance with that of other advanced silver-containing 
wound dressings.
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